Stories of Hope
Press releases
Research, people, milestones and stories from across CureSearch.
Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions…
Brave Barbie doll provides a friend through treatment for kids with cancer Bethesda, Md. – October 23, 2023 – CureSearch for Children’s Cancer and Mattel are…
Bethesda, Md. – January 18, 2023 – CureSearch for Children’s Cancer, a national nonprofit dedicated to ensuring that every child diagnosed with cancer has a safe and…
Funds to support cutting-edge immunotherapy trial for pediatric high-grade glioma Bethesda, MD – February 8, 2020 – CureSearch for Children’s Cancer has received a $1 million gift from…
FOR IMMEDIATE RELEASE Contact: Margetta Thomas, Communications Manager margetta.thomas@curesearch.org Bethesda, Md. – February 7, 2022 – CureSearch for Children’s Cancer announced today the appointment of Tina Swallow, a leader in the cyber security…
At CureSearch, we’re dedicated to bringing childhood cancer patients to the forefront of drug development, but we can’t do it alone. Long-term impact will require collaboration among…
FOR IMMEDIATE RELEASE Media Contact: Margetta Thomas, Communications Manager margetta.thomas@curesearch.org Novel immunotherapy approach could improve survival rate for acute myeloid leukemia Bethesda, Md. – September 15, 2021 – CureSearch…
FOR IMMEDIATE RELEASE Media Contact: Margetta Thomas, Communications Manager margetta.thomas@curesearch.org Collaborative forum to address the unique aspects and challenges of pediatric cancer clinical trial design Bethesda, MD –…
Stay close to the progress
Get research news, family stories and meaningful ways to help—delivered with purpose, not clutter.
By subscribing, you agree to receive email updates from CureSearch.
Every connection to CureSearch has a story. We’d love to hear yours.
Whether you’ve hiked, given, volunteered, or lived this journey yourself, your story is part of ours.
